Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

the standard of care. The study found:

-- Up to 81 percent of those patients treated with R1626 1500 mg (twice-

daily) + PEGASYS + COPEGUS had an undetectable HCV viral load by week

four (mean reduction of 5.2 log10 IU/mL)

-- ALT, a liver enzyme, normalized in approximately 50 percent of patients

in R1626 treatment groups

-- Most reported adverse events were mild to moderate. Dose dependent,

reversible grade four neutropenia was observed in the R1626 arms (36

percent in patients receiving R1626 1500 mg + PEGASYS + COPEGUS), and

was the main reason for dose reduction and discontinuation

Lack of Resistance

According to a second presentation at the conference, resistance to R1626 was not identified following intensive testing for either two weeks of treatment with R1626 as monotherapy, or in patients treated with R1626 for four weeks in combination with the standard of care. These findings suggest that there is a high barrier to the development of resistance to R1626 in vivo.

Start of Phase IIb Trial

R1626 is being progressed into Phase IIb study, called POLI 1, to further investigate the new treatment regimens of R1626, in combination with standard or lower dose of PEGASYS and standard dose of COPEGUS. This Phase IIb trial is now open and enrolling patients in eight countries, including the United States. More information about R1626 and the clinical studies can be found on http://www.roche-trials.com.

"As a clinician, I am excited by the high rates of viral negativity that were observed after four weeks of treatment with R1626 in combination with the standard of care. The design of the Phase IIb study should enable us to find the doses of R1626, PEGASYS and COPEGUS that achieve the appropriate balance between safety and efficacy," said Dr. David Nelson, Director of Hepatology and Liver Transplantation at the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... CORTLANDT MANOR, N.Y. , March 2, 2015 /PRNewswire/ ... patients screened for CRC.   During CRC Awareness Month, we ... items throughout March. , Posters – ... seating areas , CRC Patient Brochures with Stand ... , Screening Reminder Post-its – to be put on/in ...
(Date:3/2/2015)... HOUSTON, TX , March 2, 2015 /PRNewswire/ - ... today reported financial results for the first quarter and ... otherwise, are expressed in Canadian dollars and in accordance ... Summary Results ESSA recorded a net ... the three months ended December 31, 2014 (Q1-2015), compared ...
(Date:3/2/2015)... , March 2, 2015 Mount Elizabeth Novena ... Singapore to treat cancer using ... Varian Medical Systems (NYSE: VAR ).  At ... new system, which enables advanced forms of treatment including ... radiation beams to attack a tumor from outside the ...
Breaking Medicine Technology:Polymedco CDP, LLC. Promotes March as Colorectal Cancer Awareness Month 2ESSA Pharma Inc. Reports First Quarter 2015 Financial Results 2ESSA Pharma Inc. Reports First Quarter 2015 Financial Results 3ESSA Pharma Inc. Reports First Quarter 2015 Financial Results 4Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 2Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 3
... today announced that its full suite of Electronic Health ... certification under the U.S. Department of Health and Human ... IT,s Stage 1 meaningful use under provisions of the ... Austin, Texas-based Drummond Group Inc., one of the first ...
... HILL, N.C., Nov. 12, 2010 In today,s payer-driven ... new pharmaceutical product. But achieving access isn,t an end ... brand,s long-tem commercial success is tied to effective pull-through ... contract is signed. To help organizations create ...
Cached Medicine Technology:MedInformatix' EHR Solutions Achieve ONC Meaningful Use Certification 2Creating a Platform for Managed Care Pull-Through Success in 2011 2
(Date:3/3/2015)... 2015 ISI Telemanagement Solutions, Inc., a ... the 2015 Cisco Geekfest in Austin, TX on March ... together to discuss the overall architecture and future vision ... keynote address from Martin Roesh, Vice President and Chief ... will also include two days of technical presentations from ...
(Date:3/3/2015)... 2015 HealthCarePoint (HCP) , ... announced today that it has completed development of ... Interchange Standards Consortium (CDISC). HCP will continue to ... knowledge-based training and certifications globally. HCP’s in-kind services ... support as well as development of dynamic identification ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 ... user-friendly website that focuses on providing an interactive ... schools, and addiction treatment for clients ranging in ... interventions on the site have a wide variety ... spectrum disorders, severe learning disabilities, drug rehabilitation, failure ...
(Date:3/2/2015)... Bronx, NY (PRWEB) March 02, 2015 ... a nurse at their Brooklyn Satellite in Lutheran ... with this quarterly award must demonstrate excellence through ... Honorees are also expected to go above and ... “healing touch” presence with patients and their families. ...
(Date:3/2/2015)... 02, 2015 Dr. David Knepp, a ... partnering with Doctors on Liens to bring ... It’s rare for personal injury victims to have access ... on a lien basis. However, San Diego Chiropractic ... of chiropractors, M.D., pain management physician, massage, and acupuncture ...
Breaking Medicine News(10 mins):Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2015 Cisco Geekfest 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:All Kinds of Therapy – New Website for Behavioral Health and Substance Abuse Treatment Launches Today 2Health News:Calvary Hospital Honors Peter Acerios, RN, with Daisy Award 2Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2
... Canes to be Provided Nationwide, BALTIMORE, Aug. 19 ... largest organization of blind,people, today announced an initiative to ensure ... who needs a long white cane will have,one, regardless of ... to,anyone in the fifty states, the District of Columbia, or ...
... President & COO, Former Experian Executive Will Lead Private Access, ... of web-based privacy management and ... clinical trials recruitment tools, ALISO VIEJO, ... solutions that enable management of detailed,privacy preferences for personal health ...
... prevalence of obesity and overweight in the United States ... to obesity raises serious implications for the health of ... The American Journal of Gastroenterology examine the ... and gastroesophageal reflux disease, or GERD. , Dr. Frank ...
... affordable digital pathology solutions for cancer diagnosis and preclinical research, today ... led by Burrill & Company. Ascension Health Ventures, National Healthcare Services ... round with strong support. , ... CUPERTINO, Calif. ...
... will open NHPCO,s 9th Clinical Team Conference on ... Elizabeth Edwards,is deeply committed to improving America,s future. ... she has been a vocal advocate and,tireless worker ... increasing,quality healthcare in America. Mrs. Edwards will be ...
... About 13 percent of elderly Americans are mistreated, most ... advantage of them, according to a University of Chicago ... mistreatment in the country. , "The population of the ... diseases longer. So it,s important to understand, from a ...
Cached Medicine News:Health News:National Federation of the Blind Launches Largest-Ever White Cane Initiative 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 3Health News:Obesity raises risks of serious digestive health concerns 2Health News: BioImagene Raises $26 M in Expansion Capital 2Health News:Elizabeth Edwards to be Opening Speaker at National Hospice Conference in Dallas 2Health News:U. of Chicago study: More than 10 percent of older Americans suffer mistreatment 2
... Based upon the original Magstim design the ... upon the years of knowledge and expertise ... environments. Resulting in an innovative design that ... range as the system of preferred choice. ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical approach ... and visualized laser application. The ciliary body ... the surgeon, from the anterior or posterior ... The target tissues are easily and accurately ...
Medicine Products: